Rempex Pharmaceuticals Snags $67.5M

San Diego-based Rempex Pharmaceuticals, a biopharmaceuticals firm addressing antibiotic resistance, announced this morning that it has raised $67.5M in an initial close of a Series B financing round. The round came from Frazier Healthcare Ventures, Vivo Ventures, SV Life Sciences, OrbiMed Advisors and Adams Street Partners. Rempex said the new funding brings its total raised to $76M, since its founding in June. Rempex is developing treatments for resistant gram-negative infections, based on technology originally developed by Mpex Pharmaceuticals. The company is led by Daniel Burgess. More information »